Elamipretide Hydrochloride Patent Expiration

Elamipretide Hydrochloride was first introduced by Stealth Biotherapeutics Inc in its drug Forzinity on Sep 19, 2025.


Elamipretide Hydrochloride Patents

Given below is the list of patents protecting Elamipretide Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Forzinity US11083771 Feb 28, 2034 Stealth Biotheraps
Forzinity US11083772 Feb 28, 2034 Stealth Biotheraps
Forzinity US11771734 Feb 28, 2034 Stealth Biotheraps
Forzinity US12268724 Feb 28, 2034 Stealth Biotheraps
Forzinity US9687519 Feb 28, 2034 Stealth Biotheraps
Forzinity US7576061 Jan 20, 2026 Stealth Biotheraps



Elamipretide Hydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Elamipretide Hydrochloride Generic API Manufacturers

Given below is the list of companies who have filed for Elamipretide Hydrochloride generic, along with the locations of their manufacturing plants worldwide.